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The production of blood cells depends on a rare hematopoietic
stem-cell (HSC) population, but the molecular mechanisms underly-
ing HSC biology remain incompletely understood. Here, we identify
a subset of microRNAs (miRNAs) that is enriched in HSCs compared
with other bone-marrow cells. An in vivo gain-of-function screen
found that three of these miRNAs conferred a competitive advan-
tage to engrafting hematopoietic cells, whereas other HSC miRNAs
attenuated production of blood cells. Overexpression of the most
advantageous miRNA, miR-125b, caused a dose-dependent myelo-
proliferative disorder that progressed to a lethal myeloid leukemia
in mice and also enhanced hematopoietic engraftment in human
immune system mice. Our study identifies an evolutionarily con-
served subset of miRNAs that is expressed in HSCs and functions to
modulate hematopoietic output.
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Long-term production of blood cells depends on proper he-matopoietic stem-cell (HSC) function (1). This involves a del-
icate balance between HSC self-renewal and differentiation into
progenitor populations. The molecular networks that control
these processes have begun to be elucidated in recent years, and
several regulatory proteins have been shown to manage stem-cell
physiology (2–6). Additionally, there is a substantial overlap be-
tween the proteins that regulate HSC biology and those that are
dysregulated in cancers of immunological origin or other hema-
topoietic diseases, underlying the importance of these factors in
maintaining homeostasis.
Mammalian noncoding microRNAs (miRNAs) have recently
been identified as important repressors of gene expression through
direct interactions with specific mRNA targets, and thus act to
modulate gene function (7, 8). Several reports have found that
miRNAs regulate the development of specific hematopoietic line-
ages (9). Conditional deletion of Dicer, which disrupts miRNA
processing, has revealed critical roles for miRNAs during deve-
lopment of different hematopoietic lineages, including both B and
T lymphocytes (10–12). Specific miRNAs have also been shown to
impact development of distinct blood-cell lineages. Early B cell
differentiation is modulated bymiRNA (miR)-150 (13), miRNAs 17-
5p-20a-106a direct human monocytes development (14), and miR-
223 functions to restrict the granulocytic compartment in vivo (15).
Recent studies have shown a causative role for miRNAs in
mediating malignant diseases in the hematopoietic system. For
example, sustained expression of miR-155 or miR-29a in the
mouse hematopoietic system causes a myeloproliferative disor-
der (16) or leukemia (17), respectively, whereas a B cell malig-
nancy is triggered by constant expression of miR-155 in a B cell-
restricted manner (18). However, tumor suppressor miRNAs like
miR-15a/16-1 are deleted in a subset of lymphomas (19), which has
been shown to cause chronic lymphocytic leukemia in mice (20).
Despite their being clearly linked to hematopoietic develop-
ment and cancer, there is little known regarding the expression
patterns and function of mammalian miRNAs in HSC pop-
ulations. One study found that mice deficient in Ars2, which is
required for proper miRNA processing, suffer from bone-marrow
failure, suggesting a functional role for miRNAs in HSCs (21).
Other groups have profiled miRNA expression in human CD34+
cells (22). However, many of the identified miRNAs are broadly
expressed outside of HSCs, and their functional relevance in stem
cells was not investigated in vivo. In the present study, we sought
to both find specific miRNAs that are enriched in long-termHSCs
and investigate their impact on long-term hematopoietic re-
constitution.
Results
Identification of miRNAs Enriched in HSCs. To identify miRNAs
enriched in hematopoietic stem and progenitor cells (HSPCs),
we isolated lineage-negative (lin−) cKit+Sca1+ (LKS) cells
from adult C57BL6 mouse BM using FACS (Fig. 1A Upper).
Total RNA was isolated from LKS cells and also from RBC-
depleted total bone marrow (BM), and it was used to perform
a microarray analysis to identify expression of mouse miRNAs.
Some 137 miRNAs were expressed at detectable levels in the
BM and/or LKS populations. Of these, 67 were expressed at
higher levels in total BM vs. LKS cells, 59 were expressed at
similar levels in the two cellular populations, and 11 were ex-
pressed at higher levels in the LKS compartment vs. total BM
(Fig. 1A Lower and Table S1). Corroborating the microarray
results, quantitative (q) PCR detected enrichment of these 11
miRNAs in LKS cells. They are miR125a-5p, miR-125b-5p, miR-
155, miR-130a, miR196b, miR-99a, miR-126-3p, miR-181c,
miR-193b, miR-542-5p, and let7e (Fig. 1B). A more extensive
cellular fractionation of mouse BM further confirmed enrich-
ment of most of these miRNAs in the LKS subset (Fig. 1C and
Fig S1). Expression of miR-223, known to be enriched in mature
myeloid cells, was measured as a control (Fig. 1C). The LKS
population is comprised of both HSCs, capable of establishing
long-term multilineage hematopoietic engraftment, and multi-
potent progenitors, with reduced capacity to reconstitute the
hematopoietic system. LKS cells expressing the HSC marker
endothelial protein C receptor (EPCR) (23) were first analyzed,
and a higher relative expression of many of the miRNAs under
study was found in EPCR+ vs. EPCR-LKS cells (Fig. 1C). Long-
term HSCs have also been shown to be CD150+CD48-, whereas
other LKS progenitor populations are negative for CD150 (24).
Again, qPCR analysis found that most of theHSPCmiRNAs were
further enriched in CD150+CD48- long-term HSCs compared
with CD150-LKS cells (Fig. 1D). These data indicate, using
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multiple criteria to define HSCs, that this subset of miRNAs is
largely enriched in long-term HSCs.
Gain-of-Function Approach to Assess the Impact of HSC miRNAs on
Long-Term Hematopoietic Engraftment. The expression patterns of
these particular miRNAs suggest that they have a specialized role
in regulating hematopoiesis at the stem-cell level. To ascertain the
functional impact of these HSC miRNAs on long-term hemato-
poietic reconstitution, we constructed a series of murine stem-cell
virus (MSCV)-based miRNA-expression vectors that carry each
of the 11 miRNAs under study. The vectors were formatted with
mouse miR-155 arms and stem loop sequences, with each miRNA
duplex encoded by the sense and antisense stem regions (Fig. 2A).
This format was chosen because of its established ability to be
processed in hematopoietic cells (25), including HSCs, where we
have found mature miR-155 to be expressed (Fig. 1). Production
of the different mature miRNAs using this format was confirmed
in 293T cells by qPCR (Fig. S2).
Competitive repopulation experiments were performed by com-
bining equal numbers of HSC-enriched CD45.1+ bone-marrow
cells transduced with retroviruses encoding a specific HSCmiRNA
with HSC-enriched CD45.2+ bone marrow transduced with a con-
trol retrovirus. This cellularmixturewas used to reconstitute lethally
irradiated CD45.2+ C57BL6 recipients. Because the retrovectors
coexpress GFP in addition to a miRNA, the ability of the CD45.1+
miRNA-expressing bone marrow to compete with CD45.2+ con-
trol vector-containing bone marrow during hematopoietic engraft-
ment could be tracked by FACS analysis of peripheral blood
cells. Mice were bled at 2 and 4 mo postreconstitution. When both
vectors lackedamiRNA, therewas similar representationof the two
markers in the peripheral blood mononuclear cells (Fig. S3). In
three cases, including miR-125b-5p, miR-126-3p, andmiR-155, the
miRNA conferred an evident and statistically significant (P < 0.05)
competitive advantage to the engrafted bone marrow (Fig. 2B and
Fig. S3). In contrast, overexpression of several of the miRNAs
caused a significant (P < 0.05) disadvantage to the engrafted bone
marrow, with miR-196b, miR-181c, let7e, and 542-5p having the
largest impact (Fig. 2B and Fig. S3). FACS analysis of the pe-
ripheral blood was also used to determine the distribution of
different hematopoietic lineages to assess whether engraftment
was being skewed to a single lineage or was multilineage at 4 mo
postreconstitution. The effects of the different miRNAs on en-
graftment were largely multilineage, consistent with these miR-
NAs regulating stem-cell homeostasis (Fig. 2C).
miR-125b Causes a Dose-Dependent Myeloproliferative Disorder That
Progresses to a Myeloid Leukemia. We next focused on further
characterization of miR-125b, because it had the largest positive
impact on competitive reconstitution among the miRNAs tested
and is overexpressed in certain types of acute myeloid leukemia
(AML), suggesting that it plays an active role in human malig-
nancies (26, 27). miR-125b is expressed from two loci in the
genome, and these sequences are referred to as miR-125b1 and
miR-125b2. To assess the impact of expressing miR-125b with its
native arms and loop sequences, we cloned segments of the miR-
125b1 and miR-125b2 primary transcripts into our retroviral ex-
Fig. 1. Identification of miRNAs enriched in HSCs. (A) Microarray experi-
ment comparing miRNA expression in the LKS compartment (FACS plot in
Upper and subset boxed in red) with total bone marrow from C57BL6 mice.
Number of miRNAs significantly enriched in total BM vs. the LKS compart-
ment, unchanged between the two groups, or significantly enriched in LKS
vs. total BM cells are shown (Lower). BM cells were pooled from 10 mice and
sorted, and RNA was extracted for the microarray. (B) qPCR was used to
determine the fold enrichment of the 11 miRNAs preferentially expressed in
LKS cells vs. total BM. Data represent two independent experiments. (C)
Expression levels of the 11 HSPC miRNAs were measured in hematopoietic
cells from the different bone-marrow compartments shown in Fig. S1 and
represent different stages of blood-cell development. (D) LKS-gated cells
were further sorted by FACS into three groups according to their expression
of the signaling lymphocytic activation molecule (SLAM) markers CD150 and
CD48. Total RNA was collected from each group, and the relative expression
levels of miRNAs from each LKS subpopulation were assayed by qPCR. Data
represent two independent experiments, each starting with pooled BM from
20 mice. All data were normalized to sno202 and represent the mean + SEM.
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pression system (Fig. 3A). We found that these cassettes led to
substantially increased expression levels of mature miR-125b in
K562 cells compared with the miR-125b cassette formatted with
miR-155 arms and loop sequences [used above and now referred
to as 125b(f)], likely a result of more efficient processing (Fig.
3A). Furthermore, miR-125b1 expression was higher than miR-
125b2, providing three vectors with conveniently graded ex-
pression of miR-125b.
Mice were subsequently reconstituted with bone marrow ex-
pressing miR-125b1, miR-125b2, or control vector, and a sepa-
rate cohort of mice expressing miR-125b(f) or its vector control
was also established. All mice from both groups were bled after 2
mo of reconstitution, and complete blood cell counts (CBCs)
were recorded (Fig. 3B). Mice expressing miR-125b, regardless
of the construct used, had subtly elevated total WBC counts
compared with control mice. Reconstitution of mice with HSPCs
expressing the lowest levels of miR-125b, miR-125b(f), resulted
in a general increase in all WBC compartments analyzed, in-
cluding myeloid, lymphoid, and platelets, but did not impact
RBCs. However, mice with the more highly expressed endoge-
nous miR-125b1 or b2 vectors exhibited a clear myeloproliferative
disorder (MPD) that was characterized by increased absolute
numbers of monocytes and neutrophils and decreased levels of
lymphocytes, RBCs, and platelets. Peripheral blood from miR-
125b-1– and miR-125b-2–expressing mice, compared with control
mice, also had dramatic increases in the percentage of CD11b+
myeloid cells, many of which were also Gr1+ as assayed by
FACS (Fig. 3C).
Analysis of Wright-stained bone-marrow smears from miR-
125b(f)mice 2mo postreconstitution revealed amild expansion of
myeloid cells in the bone marrow, whereas H&E-stained spleen
sections were similar to those from control mice (Fig. S4). How-
ever, miR-125b1– and miR-125b2–expressing mice exhibited
myeloid-dominated BM and spleens as well as myeloid-cell in-
filtration into the liver (Fig. S4). By 3.5 mo postreconstitution,
miR-125b1 and miR-125b2 mice had substantially increased
WBCs in their peripheral blood consisting mainly of immature
granulocytic and monocytic cells (Fig. S4). Shortly after, the
condition became lethal for most of the mice expressing the
highest levels of miR-125b, with tumor infiltration evident in
the spleen and liver (Fig. 4 A and B). The surviving miR-125b2
mice had progressively increasingWBC counts and higher levels of
leukemic blasts in their peripheral blood from 3.5 to 4.5 mo post-
reconstitution and also eventually succumbed to leukemia (Fig. 4A
and C). Furthermore, transfer of malignant BM from moribund
miR-125b1–expressing mice to immunodeficient Rag2−/−γc−/− sec-
ondary recipients resulted in death within weeks, whereas transfer
of BM from control mice had no impact on survival (Fig. 4D).
These findings show a dose-dependent sufficiency of miR-125b to
drive pathological myeloid-cell expansion, a condition that pro-
gresses to an aggressive myeloid leukemia.
Evolutionarily Conserved miRNA Expression and Function in Human
CD34+ HSPCs. We investigated whether the subset of miRNAs
enriched in mouse HSCs was also enriched in human CD34+
HSPCs. RNA was prepared from CD34+ and CD34− umbilical
cord blood (CB) peripheral blood mononuclear cell (PBMC)s and
analyzed by qPCR. With the exception of miR-193b, all of the
miRNAs showed significant enrichment in the CD34+ HSPC
cellular subset comparedwithmature CD34−PBMCs (Fig. 5A). To
determine whether miR-125b could also impact human hemato-
poietic engraftment, CD34+CB cells were transduced with control
Fig. 2. Gain-of-function approach to assess the impact of HSC miRNAs on long-term hematopoietic reconstitution. (A) HSC miRNAs were cloned into an
MSCV-based retroviral vector (MG) using an miR-155 arms and loop format. (B) Competitive BM reconstitutions were performed using C57BL6 mice to assess
the engraftment potential of BM expressing each of the 11 HSC miRNAs (CD45.1 cells) compared with control BM (CD45.2 cells). GFP was used to identify cells
containing a vector. A 4-mo time course showing the percentage of CD45.1+GFP+ cells in the peripheral blood of each group of mice is shown. The ex-
periment was broken into two batches (Upper and Lower), each with its own negative control. (C) Lineage analysis of the CD45.1+GFP+ peripheral blood cells
at the 4-mo time point was assessed by determining the percentages of B220+ (B cell), CD3+ (T cell), and CD11b+ (myeloid cell) in each group. Data represent
the mean + SEM. Experiments had four mice per group.
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or a miR-125b1–expressing lentiviral vector (Fig. 5B) and subse-
quently injected intrahepatically into newborn Rag2−/−γc−/− mice
on a BALB/c genetic background generating the previously de-
scribed human immune system (HIS) model (28). After 10 wk,
peripheral blood was collected and analyzed for the presence of
human CD45+ WBCs by FACS, and a dose-dependent enhance-
ment in multilineage engraftment was observed in miR-125b1–
expressing vs. control HIS mice (Fig. 5 C–E). At 12 wk post-
reconstitution, the high-dose (multiplicity of infection [MOI] 40)
groups were harvested, and miR-125b–expressing HIS mice had
significantly elevated levels of human (h)CD45+ cells and hCD34+
HSPCs in their bone marrow (Fig. 5 F and G). These data provide
evidence that miR-125b also promotes hematopoietic engraftment
of human HSCs.
Discussion
In this work, we have identified an evolutionarily conserved
subset of miRNAs that is enriched in HSCs and have provided
evidence that these miRNAs function to properly manage he-
matopoietic output. Because some miRNAs promoted whereas
others diminished hematopoietic engraftment, it is possible that
these HSCmiRNAs work in a concerted manner to ensure proper
output of blood cells. A similar paradigm has recently been shown
for ES cells, where opposing miRNA families modulate ES cell
self-renewal and differentiation (29). This suggests that regulatory
networks involving multiple miRNAs participate in the control of
both embryonic and adult stem cells.
Owing to their important developmental roles and ability to
target known oncogenes and tumor suppressors (9), miRNAs
are a key part of the intricate molecular networks that drive or
suppress cancer development and progression. Certain hemato-
poietic cancers, such as chronic myeloid leukemia (CML), are
sustained by rare cancer stem-cell populations that have signifi-
cant mRNA expression overlap with normal HSCs, despite
producing malignant progeny (30). Our newly identified set of
HSC miRNAs might prove to be useful as biomarkers of such
cancer stem-cell populations. In the case of miR-125b, it will also
be of interest to assess whether it transforms HSCs or a com-
mitted myeloid progenitor and to characterize secondary muta-
tions that may assist in this process.
Fig. 3. miR-125b causes a dose-dependent MPD. (A) The three constructs
used to enforce expression of miR-125b are shown. K562 cells were trans-
duced with each retrovector, and miR-125b levels were assayed by qPCR. (B)
Blood concentrations of the indicated cell types are shown for mice
expressing MG, MG-125b1, MG-125b2, and in a separate experiment (sepa-
rated by a dashed line), MG and MG-125b(f) 2-mo postreconstitution. (C)
FACS plot showing a representative FACS plot of Gr1+CD11b+ cells in the
peripheral blood of mice overexpressing miR-125b2, miR-125b1, or control
vector 2 mo postreconstitution. Asterisk denotes a P value < 0.05.
Fig. 4. MPDs caused by miR-125b progress to myeloid leukemia in a dose-
dependent manner. (A) Survival of mice expressing different levels of miR-
125b. (B) Liver and spleen from miR-125b2–expressing mice with leukemia
4.5 mo after reconstitution. Representative H&E-stained tissue sections of
each respective organ taken from miR-125b2–expressing mice are shown on
Right. (C) Percentage of leukemic blasts in the peripheral blood of control or
miR-125b2–expressing mice 3.5 and 4.5 mo postreconstitution, and repre-
sentative Wright-stained blood smears from miR-125b2 mice at each time
point. Examples of blasts are indicated by red arrows. (D) Survival of mice
after i.v. transfer of malignant MG-125b1 (four different donors) or MG
control bone marrow to Rag2−/−γc−/− recipients (n = 3–6 mice per group).
Asterisk denotes a P value < 0.05.
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Many of the miRNAs identified in our study, including miR-
125b, miR-155, miR-126, miR-196b, and miR-99a, have been
shown to be dysregulated in different subsets of AML (31). Be-
cause we have shown functional relevance for many of these HSC
miRNAs in vivo, including the abilities of miR-155 (16) and now
miR-125b to trigger aggressive MPDs and myeloid leukemia, re-
spectively, therapeutic targeting of this subset may be effective in
combating hematopoietic cancers.
Materials and Methods
All animal experiments were approved by the institution animal care and use
committee (IACUC) at Caltech. HSPCs were isolated from C57BL6 bone
marrow using MACS (Miltenyi) followed by FACS sorting (antibodies de-
scribed in Table S2), and total RNA was collected from equal numbers of cells
by miRNeasy (Qiagen) and was used to quantitate miRNA expression by
microarray (Agilent) and qPCR (ABI Taqman). Cell culture, retroviral trans-
duction, bone-marrow transplants, CBCs, FACS, and histopathology were
performed as described previously (16). For competitive bone-marrow
reconstitutions, C57BL6 mice expressing the congenic markers CD45.1 and
CD45.2 were used as bone-marrow donors, and CD45.2 mice were used as
recipients. Equal numbers of 5-Fluorouracil (5-FU)–treated bone-marrow
cells from each group were infected with an miRNA-expressing (CD45.1 cells)
or control vector (CD45.2 cells), and a 1:1 cell mixture was injected i.v. into
lethally irradiated mice. miRNA-expression vectors formatted with miR-155
loop and arms were constructed as described previously (Table S3 shows
oligonucleotide sequences) (25). Endogenous miR-125b sequences were
obtained from System Biosciences and were PCR cloned into MG and MGP
retrovectors or a third-generation replication-deficient lentiviral vector.
Human cell work was approved by the Institute Biosafety Committee (IBC) at
Caltech. HIS mice were generated by injecting 2 × 105 lentivirus transduced
CD34+ CB cells i.h. into irradiated newborn Rag2−/−γc−/− mice on a BALB/c
genetic background as described (28). Expanded methods are found in SI
Materials and Methods.
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Fig. 5. Evolutionarily conserved miRNA expression and function in human CD34+ HSPCs. (A) Human CB was sorted into CD34+ (HSPC+) and CD34− (HSPC−)
fractions. Expression of the miRNAs enriched in mouse HSCs was measured by qPCR. Data are normalized to RNU48 and presented as mean + SEM (n = 3
different donors). (B) Human CB CD34+ cells were transduced with control or miR-125b1–expressing lentiviral vectors at an MOI of ∼4 or 40, and miR-125b
levels were assayed by qPCR. (C) Representative FACS plots showing an increased ratio of human to mouse CD45+ WBCs in the peripheral blood of miR-125b–
expressing HIS mice 10 wk after CD34+ cell injection. (D) A gray dot represents each mouse. (E) Human cells in the peripheral blood of high-dose (MOI 40) HIS
mice were analyzed by FACS for the expression of different lineage markers including CD19 (B cells) and CD33 (myeloid). Data are represented as the mean ±
SEM. (F) A representative FACS plot of hCD45+ and hCD34+ cells in the BM of miR-125b–expressing and control vector HIS mice 12 wk post-CD34+ injection.
(G) A gray dot represents each mouse. Asterisk denotes a P value < 0.05.
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